mProX™ Human SIGLEC8 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

SIGLEC8 is a lectin found in immune cells that plays a regulatory role by recognizing self-associated glycans and inhibiting immune cell functions. It has a high degree of specificity for sialyl N-acetyllactosamine (sLacNAc) with specific sulfations. The sequence variety in the CC' loop of SIGLEC8, SIGLEC9, and SIGLEC3 determines their recognition of sulfated oligosaccharides. SIGLEC8 has been studied as a potential therapeutic target for mast cell-mediated diseases, such as urticaria. Mast cell silencing, achieved through the engagement of inhibitory receptors like SIGLEC8, is a novel therapeutic approach for these diseases. In addition, SIGLEC8 has been identified as a hub gene in psoriasis, suggesting its potential as a diagnostic biomarker and therapeutic target. Furthermore, SIGLEC8 and other Siglecs have been explored as potential targets for therapy in mast cell- and eosinophil-associated diseases. Lirentelimab, a monoclonal antibody against SIGLEC8, has been investigated in a clinical trial for refractory indolent systemic mastocytosis and has shown safety, tolerability, and efficacy in reducing symptoms. Overall, SIGLEC8 has diverse applications in understanding disease mechanisms, developing diagnostic biomarkers, and exploring therapeutic interventions.